Stock KRYS KRYSTAL BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
159 USD -2.35% Intraday chart for Krystal Biotech, Inc. -4.69% +28.16%
May. 23 Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing MT
May. 14 Transcript : Krystal Biotech, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing
Krystal Biotech Swings to Q1 Profit -- Shares Fall
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong
Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing
Sector Update: Health Care Stocks Ease Late Afternoon
Sector Update: Health Care Stocks Weaker Monday Afternoon
Top Midday Gainers
Krystal Biotech Shares Jump After Surprise Q4 Profit
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
MORNING BID AMERICAS-Booming stocks step back as PCE hoves into view
Krystal Biotech Says FDA Grants Fast Track Designation to Inhaled KB707 for Lung Tumors Treatment
Krystal Biotech Secures J-code for Vyjuvek
Krystal Biotech Receives Permanent J-Code for VYJUVEK®
Krystal Biotech Says Japan Grants Orphan Drug Designation to Skin Disease Treatment; Shares Rise Pre-Bell
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRYS Stock
  4. News Krystal Biotech, Inc.
  5. Other languages